MDA 2020 poster: Demographic and safety data from patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in the STRIDE Registry
The key demographic and safety data from an observational drug registry of patients with nmDMD receiving a mutation-specific DMD therapy are presented in our poster at MDA 2020
The demographics and characteristics of patients enrolled in the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry effectiveness population, overall and stratified by corticosteroid use, are presented
Information regarding the safety and tolerability of the mutation-specific DMD therapy as evaluated by the analysis of treatment-emergent adverse events and serious adverse events is included
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.